<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01677637</url>
  </required_header>
  <id_info>
    <org_study_id>2011-BOD-EL-02</org_study_id>
    <nct_id>NCT01677637</nct_id>
  </id_info>
  <brief_title>Osteoporosis Screening Trial</brief_title>
  <acronym>OSTRIA</acronym>
  <official_title>Epidemiological, Observational, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elpen Pharmaceutical Co. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elpen Pharmaceutical Co. Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoporosis is the most common disease of bone and characterized firstly by low bone mass&#xD;
      and secondly, impaired bone microarchitecture structure resulting in reduced strength and&#xD;
      increased risk of fracture. Osteoporosis is divided into: primary (Postmenopausal&#xD;
      Osteoporosis Osteoporosis &amp; elderly and senile osteoporosis) and secondary. The most common&#xD;
      form is postmenopausal osteoporosis. It occurs in women after menopause and is associated&#xD;
      with decreased estrogen production, which normally occurs at this age women Osteoporosis&#xD;
      usually occurs after age 50, it is very common in women than in men, and its frequency&#xD;
      increases with advancing age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the findings of epidemiological studies in different countries, osteoporosis&#xD;
      affects 25-35% of women and 15-20% of men aged 50 and over. In terms of our country in the&#xD;
      recent nation-epidemiological research on rheumatic diseases in the general adult population,&#xD;
      ie persons aged 19 and over, organized and conducted by the Greek Institute of Rheumatology&#xD;
      Research, became a separate study on frequency of osteoporosis in women aged 50 years and&#xD;
      above. These women was measured BMD at the lumbar spine and at the upper end of the femur and&#xD;
      found that 28.4% of Greek women aged 50 and over have osteoporosis. It is indeed very&#xD;
      interesting finding in this study that women who have osteoporosis, the vast majority, ie&#xD;
      about 75%, I do not know. This is of particular importance and highlights the need to educate&#xD;
      and inform systematically the public, especially women regarding both the modern&#xD;
      possibilities for early diagnosis of osteoporosis, and for the implementation of primary and&#xD;
      secondary prevention.&#xD;
&#xD;
      Osteoporosis is a major public health problem for two reasons: First, because it is common,&#xD;
      and secondly because it has significant impact on patients and their families, the health&#xD;
      system and the national economy.&#xD;
&#xD;
      The main clinical manifestation of osteoporosis is fractures low energy, ie fractures&#xD;
      occurring after mild degree injury, eg fall from a standing position. Approximately 40% of&#xD;
      cases osteoporotic fractures on the vertebrae, 20% in the femoral neck, 20% to 20% radius and&#xD;
      several other bones. While osteoporosis is generally regarded as a disease of women, however,&#xD;
      as already mentioned above, osteoporosis affects and men. It has even been found that 30% of&#xD;
      osteoporotic fractures of the femoral neck and 20% of osteoporotic vertebral fractures occur&#xD;
      in men.&#xD;
&#xD;
      The risk of fractures of the hip, vertebrae and radius increases with advancing age in both&#xD;
      women and men. It has even been estimated that the risk of osteoporotic fracture in women&#xD;
      aged 50 and over is 40-50% and 15-20% in men.&#xD;
&#xD;
      The adverse effects of osteoporosis patients and their families, the health system and the&#xD;
      national economy due to fractures. Indicative only some of these effects:&#xD;
&#xD;
        -  The mortality in patients with hip fractures and clinically symptomatic vertebral&#xD;
           fractures is significantly higher than that observed in individuals of the same sex and&#xD;
           similar age in the general population. For example, within the first year after the&#xD;
           fracture approximately 20% of patients with hip fracture and 25% of patients with&#xD;
           vertebral fracture die.&#xD;
&#xD;
        -  One year after a hip fracture, only 50% of patients can execute without help ordinary&#xD;
           activities of everyday life.&#xD;
&#xD;
        -  On an annual basis the number of days of hospitalization for patients with osteoporotic&#xD;
           fractures is significantly greater than the number of days of hospitalization required&#xD;
           for patients with stroke or diabetes mellitus or myocardial infarction or breast cancer.&#xD;
&#xD;
      Moreover, in 2000 the European Union the then 15 Member States (total population of&#xD;
      379,000,000 people) is estimated to have occurred 3.79 million osteoporotic fractures and&#xD;
      that the direct costs of these fractures (costs of hospitalization, surgery and medical care)&#xD;
      was approximately 32 billion Euros.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Osteoporosis Indicator</measure>
    <time_frame>1 year</time_frame>
    <description>T-score per female as measured by Holofic Sahara Instrument</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5500</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>All measurements</arm_group_label>
    <description>Total measured population</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Postmenopausal females screened for osteoporosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females&#xD;
&#xD;
          -  Postmenopausal women&#xD;
&#xD;
          -  Outpatients screened for osteoporosis&#xD;
&#xD;
          -  Women &gt; 45 years&#xD;
&#xD;
          -  Women &lt; 45 years under menopause&#xD;
&#xD;
          -  Women obtained their consent to be measured&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Premenopausal females&#xD;
&#xD;
          -  Women without any symptom of menopause&#xD;
&#xD;
          -  Women not obtained their consent to be measured&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aristeidis Kerasiotis, Endocrinologist</last_name>
    <role>Study Chair</role>
    <affiliation>Director of Endocrinology Unit ,'Iaso' Hospital of Athens, 37-39 Kifisias avenue, 15123, Athens, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioannis Lentzas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Medical State Center, Simopoulo, Perfecture of Ilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dimitrios Tsorntanidis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Registrat B', Medical State Center, Erymantheia, Achaia Perfecture</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Chronopoulou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Registrat B', Medical State Site, Diakofto, Achaia Perfecture</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olimpia Raftopoulou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Registrat B', Medical State Site, Myrsini, Perfecture of Ilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stylianos Danelakis, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Leontari</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Simos, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Anavra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theofanis Tsirogiannis, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Agnantero</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konstantinos Vatalis, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Tsartsani</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioannis Antonopoulos, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Ampelonas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Labros Kontovos, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Nikaia, Perfecture of Larisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chara Kalliora, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Gomfon, Perfecture of Trikala</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios Misios, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Megala Kalyvia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonis Monastiriotis, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Oropos - Chalkoutsi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zeppos Monstratos, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Marathonas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Sakellaropoulos, Orthop.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Marathonas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Sotiriou, Orthop.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Office, Zografou, Athens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Degaiti, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Site, Ano Mera, Island of Mykonos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aristeidis Frydas, Medical Internist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Medical State Center, Plomari, Island of Lesvos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolaos Tsamouras, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Center, Agiassos, Island of Lesvos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioannis Komninos, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Center of Neapolis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolaos Tsakountakis, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Center of Kastelli, Creta Island</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanouel Paterakis, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Madical Office, Heraklion, Creta Island</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Panagiota Gourgoulia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional State Medical Center of Giannouli - Tyrnavos, Perfecture of Larisa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zisis Kelepouris, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional State Medical Center Platanos-Raxa, Perfecture of Trikala, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Ganochoritis, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Center of Pyrgetos and Egani, Regional Perfecture of Larisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Demetra Zambouka, GP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical State Center of Agioi Anargyri, Regional Perfecture of Larisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charalampos Terzopoulos, MD, Orthopedics</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private office, Zografou, Athens, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Sakellariou, MD, Pathology, Registrat A</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center of Farkadona, Thessalia, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aglaia Roganaki, MD, Registrat B,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peripheral Medical Center of Mitropolis, Thessalia, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vasilis Delezos, MD, Registrat B</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center of Sophades, Thessalia, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victoria Katsouri, MD, Registrat B</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center of Sophades, Thessalia, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Papala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Medical Center of Tyrnavos, Thessalia, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Styliani Papakosta, MD, Phyciatry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Private Office, Larisa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios Tsivgoulis, MD in Physiatry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Diagnosis Center, Lesvos Island, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petros Prokopis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Office of Avlona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Papadimitriou, MD, Orthopedics</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Medical Office, Vari Attikis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vasilios Hamos, MD, Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Medical Cener, Agia, Larissa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lemonia Arvanitakou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Medical Center, Agia, Larissa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victoria Rizou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Medical Office, Halki, Larissa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vassiliki Mamakou, MD, Internist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mytilini</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonios Partsinevelos, MD, Orth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Office, Marousi, Athens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Patoulis, MD, Orth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Office, Marousi, Athens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iaso Hospital of Athens, Center of Endocrinology and Bone Metabolism</name>
      <address>
        <city>Athens</city>
        <state>Kifisias Avenue, 37-39, Maroussi</state>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994 Nov;4(6):368-81. doi: 10.1007/BF01622200.</citation>
    <PMID>7696835</PMID>
  </reference>
  <reference>
    <citation>McClung M. Difference in Distribution of T-scores Among Bone Density Tests in Postmenopausal Women. Bone Vol. 23, (5S), pg. S193, 1998.</citation>
  </reference>
  <reference>
    <citation>Ikeda Y, Iki M, Morita A, Aihara H, Kagamimori S, Kagawa Y, Matsuzaki T, Yoneshima H, Marumo F; JPOS Study Group. Age-specific values and cutoff levels for the diagnosis of osteoporosis in quantitative ultrasound measurements at the calcaneus with SAHARA in healthy Japanese women: Japanese population-based osteoporosis (JPOS) study. Calcif Tissue Int. 2002 Jul;71(1):1-9. doi: 10.1007/s00223-001-2079-6. Epub 2002 Jun 20.</citation>
    <PMID>12200654</PMID>
  </reference>
  <reference>
    <citation>Magkos F, Manios Y, Babaroutsi E, Sidossis LS. Quantitative ultrasound calcaneus measurements: normative data for the Greek population. Osteoporos Int. 2005 Mar;16(3):280-8. doi: 10.1007/s00198-004-1670-x. Epub 2004 Jul 6.</citation>
    <PMID>15241583</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>August 30, 2012</study_first_submitted>
  <study_first_submitted_qc>August 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2012</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteopenia, postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01677637
org study id: 2011-BOD-EL-02
nct id: NCT01677637
lead sponsor: 
has dmc: No
Osteoporosis is the most common disease of bone and characterized firstly by low bone mass
      and secondly, impaired bone microarchitecture structure resulting in reduced strength and
      increased risk of fracture. Osteoporosis is divided into: primary (Postmenopausal
      Osteoporosis Osteoporosis & elderly and senile osteoporosis) and secondary. The most common
      form is postmenopausal osteoporosis. It occurs in women after menopause and is associated
      with decreased estrogen production, which normally occurs at this age women Osteoporosis
      usually occurs after age 50, it is very common in women than in men, and its frequency
      increases with advancing age.
According to the findings of epidemiological studies in different countries, osteoporosis
      affects 25-35% of women and 15-20% of men aged 50 and over. In terms of our country in the
      recent nation-epidemiological research on rheumatic diseases in the general adult population,
      ie persons aged 19 and over, organized and conducted by the Greek Institute of Rheumatology
      Research, became a separate study on frequency of osteoporosis in women aged 50 years and
      above. These women was measured BMD at the lumbar spine and at the upper end of the femur and
      found that 28.4% of Greek women aged 50 and over have osteoporosis. It is indeed very
      interesting finding in this study that women who have osteoporosis, the vast majority, ie
      about 75%, I do not know. This is of particular importance and highlights the need to educate
      and inform systematically the public, especially women regarding both the modern
      possibilities for early diagnosis of osteoporosis, and for the implementation of primary and
      secondary prevention.

      Osteoporosis is a major public health problem for two reasons: First, because it is common,
      and secondly because it has significant impact on patients and their families, the health
      system and the national economy.

      The main clinical manifestation of osteoporosis is fractures low energy, ie fractures
      occurring after mild degree injury, eg fall from a standing position. Approximately 40% of
      cases osteoporotic fractures on the vertebrae, 20% in the femoral neck, 20% to 20% radius and
      several other bones. While osteoporosis is generally regarded as a disease of women, however,
      as already mentioned above, osteoporosis affects and men. It has even been found that 30% of
      osteoporotic fractures of the femoral neck and 20% of osteoporotic vertebral fractures occur
      in men.

      The risk of fractures of the hip, vertebrae and radius increases with advancing age in both
      women and men. It has even been estimated that the risk of osteoporotic fracture in women
      aged 50 and over is 40-50% and 15-20% in men.

      The adverse effects of osteoporosis patients and their families, the health system and the
      national economy due to fractures. Indicative only some of these effects:

        -  The mortality in patients with hip fractures and clinically symptomatic vertebral
           fractures is significantly higher than that observed in individuals of the same sex and
           similar age in the general population. For example, within the first year after the
           fracture approximately 20% of patients with hip fracture and 25% of patients with
           vertebral fracture die.

        -  One year after a hip fracture, only 50% of patients can execute without help ordinary
           activities of everyday life.

        -  On an annual basis the number of days of hospitalization for patients with osteoporotic
           fractures is significantly greater than the number of days of hospitalization required
           for patients with stroke or diabetes mellitus or myocardial infarction or breast cancer.

      Moreover, in 2000 the European Union the then 15 Member States (total population of
      379,000,000 people) is estimated to have occurred 3.79 million osteoporotic fractures and
      that the direct costs of these fractures (costs of hospitalization, surgery and medical care)
      was approximately 32 billion Euros.
time perspective: Prospective
measure: Osteoporosis Indicator
time frame: 1 year
description: T-score per female as measured by Holofic Sahara Instrument
arm group label: All measurements
description: Total measured population
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: Female
minimum age: 30 Years
maximum age: 90 Years
healthy volunteers: No
last name: Aristeidis Kerasiotis, Endocrinologist
role: Study Chair
affiliation: Director of Endocrinology Unit ,'Iaso' Hospital of Athens, 37-39 Kifisias avenue, 15123, Athens, Greece
last name: Ioannis Lentzas, MD
role: Principal Investigator
affiliation: Director, Medical State Center, Simopoulo, Perfecture of Ilia
last name: Dimitrios Tsorntanidis, MD
role: Principal Investigator
affiliation: Registrat B', Medical State Center, Erymantheia, Achaia Perfecture
last name: Maria Chronopoulou, MD
role: Principal Investigator
affiliation: Registrat B', Medical State Site, Diakofto, Achaia Perfecture
last name: Olimpia Raftopoulou, MD
role: Principal Investigator
affiliation: Registrat B', Medical State Site, Myrsini, Perfecture of Ilia
last name: Stylianos Danelakis, GP
role: Principal Investigator
affiliation: Medical State Site, Leontari
last name: Thomas Simos, GP
role: Principal Investigator
affiliation: Medical State Site, Anavra
last name: Theofanis Tsirogiannis, GP
role: Principal Investigator
affiliation: Medical State Site, Agnantero
last name: Konstantinos Vatalis, GP
role: Principal Investigator
affiliation: Medical State Site, Tsartsani
last name: Ioannis Antonopoulos, GP
role: Principal Investigator
affiliation: Medical State Site, Ampelonas
last name: Labros Kontovos, GP
role: Principal Investigator
affiliation: Medical State Site, Nikaia, Perfecture of Larisa
last name: Chara Kalliora, GP
role: Principal Investigator
affiliation: Medical State Site, Gomfon, Perfecture of Trikala
last name: Athanasios Misios, GP
role: Principal Investigator
affiliation: Medical State Site, Megala Kalyvia
last name: Antonis Monastiriotis, GP
role: Principal Investigator
affiliation: Medical State Site, Oropos - Chalkoutsi
last name: Zeppos Monstratos, GP
role: Principal Investigator
affiliation: Medical State Site, Marathonas
last name: George Sakellaropoulos, Orthop.
role: Principal Investigator
affiliation: Medical State Site, Marathonas
last name: Andreas Sotiriou, Orthop.
role: Principal Investigator
affiliation: Private Office, Zografou, Athens
last name: Maria Degaiti, GP
role: Principal Investigator
affiliation: Medical State Site, Ano Mera, Island of Mykonos
last name: Aristeidis Frydas, Medical Internist
role: Principal Investigator
affiliation: Director, Medical State Center, Plomari, Island of Lesvos
last name: Nikolaos Tsamouras, GP
role: Principal Investigator
affiliation: Medical State Center, Agiassos, Island of Lesvos
last name: Ioannis Komninos, GP
role: Principal Investigator
affiliation: Medical State Center of Neapolis
last name: Nikolaos Tsakountakis, GP
role: Principal Investigator
affiliation: Medical State Center of Kastelli, Creta Island
last name: Emmanouel Paterakis, GP
role: Principal Investigator
affiliation: Private Madical Office, Heraklion, Creta Island
last name: Panagiota Gourgoulia, MD
role: Principal Investigator
affiliation: Regional State Medical Center of Giannouli - Tyrnavos, Perfecture of Larisa, Greece
last name: Zisis Kelepouris, GP
role: Principal Investigator
affiliation: Regional State Medical Center Platanos-Raxa, Perfecture of Trikala, Greece
last name: Christos Ganochoritis, GP
role: Principal Investigator
affiliation: Medical State Center of Pyrgetos and Egani, Regional Perfecture of Larisa
last name: Demetra Zambouka, GP
role: Principal Investigator
affiliation: Medical State Center of Agioi Anargyri, Regional Perfecture of Larisa
last name: Charalampos Terzopoulos, MD, Orthopedics
role: Principal Investigator
affiliation: Private office, Zografou, Athens, Greece
last name: John Sakellariou, MD, Pathology, Registrat A
role: Principal Investigator
affiliation: Medical Center of Farkadona, Thessalia, Greece
last name: Aglaia Roganaki, MD, Registrat B,
role: Principal Investigator
affiliation: Peripheral Medical Center of Mitropolis, Thessalia, Greece
last name: Vasilis Delezos, MD, Registrat B
role: Principal Investigator
affiliation: Medical Center of Sophades, Thessalia, Greece
last name: Victoria Katsouri, MD, Registrat B
role: Principal Investigator
affiliation: Medical Center of Sophades, Thessalia, Greece
last name: Maria Papala, MD
role: Principal Investigator
affiliation: State Medical Center of Tyrnavos, Thessalia, Greece
last name: Styliani Papakosta, MD, Phyciatry
role: Principal Investigator
affiliation: Medical Private Office, Larisa, Greece
last name: Athanasios Tsivgoulis, MD in Physiatry
role: Principal Investigator
affiliation: Medical Diagnosis Center, Lesvos Island, Greece
last name: Petros Prokopis, MD
role: Principal Investigator
affiliation: Medical Office of Avlona
last name: George Papadimitriou, MD, Orthopedics
role: Principal Investigator
affiliation: Private Medical Office, Vari Attikis
last name: Vasilios Hamos, MD, Director
role: Principal Investigator
affiliation: State Medical Cener, Agia, Larissa
last name: Lemonia Arvanitakou, MD
role: Principal Investigator
affiliation: State Medical Center, Agia, Larissa
last name: Victoria Rizou, MD
role: Principal Investigator
affiliation: State Medical Office, Halki, Larissa
last name: Vassiliki Mamakou, MD, Internist
role: Principal Investigator
affiliation: Mytilini
last name: Antonios Partsinevelos, MD, Orth
role: Principal Investigator
affiliation: Private Office, Marousi, Athens
last name: George Patoulis, MD, Orth
role: Principal Investigator
affiliation: Private Office, Marousi, Athens
facility: 
country: Greece
citation: Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994 Nov;4(6):368-81. doi: 10.1007/BF01622200.
PMID: 7696835
citation: McClung M. Difference in Distribution of T-scores Among Bone Density Tests in Postmenopausal Women. Bone Vol. 23, (5S), pg. S193, 1998.
citation: Ikeda Y, Iki M, Morita A, Aihara H, Kagamimori S, Kagawa Y, Matsuzaki T, Yoneshima H, Marumo F; JPOS Study Group. Age-specific values and cutoff levels for the diagnosis of osteoporosis in quantitative ultrasound measurements at the calcaneus with SAHARA in healthy Japanese women: Japanese population-based osteoporosis (JPOS) study. Calcif Tissue Int. 2002 Jul;71(1):1-9. doi: 10.1007/s00223-001-2079-6. Epub 2002 Jun 20.
PMID: 12200654
citation: Magkos F, Manios Y, Babaroutsi E, Sidossis LS. Quantitative ultrasound calcaneus measurements: normative data for the Greek population. Osteoporos Int. 2005 Mar;16(3):280-8. doi: 10.1007/s00198-004-1670-x. Epub 2004 Jul 6.
PMID: 15241583
responsible party type: Sponsor
mesh term: Osteoporosis